[PDF][PDF] Emerging immunotherapy for HCC: A guide for hepatologists
HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …
Immune-related adverse events of checkpoint inhibitors
Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …
cancers. While these immunotherapies have improved patient outcomes in many clinical …
A review of cancer immunotherapy toxicity
LB Kennedy, AKS Salama - CA: a cancer journal for clinicians, 2020 - Wiley Online Library
Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy,
manipulate the immune system to recognize and attack cancer cells. These therapies have …
manipulate the immune system to recognize and attack cancer cells. These therapies have …
Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer
C Dolladille, S Ederhy, M Sassier, J Cautela… - JAMA …, 2020 - jamanetwork.com
Importance Limited information is available on the safety of a rechallenge with an immune
checkpoint inhibitor (ICI) after an immune-related adverse event (irAE). Objective To identify …
checkpoint inhibitor (ICI) after an immune-related adverse event (irAE). Objective To identify …
Mesenchymal stem cell‐derived extracellular vesicles with high PD‐L1 expression for autoimmune diseases treatment
Autoimmune diseases are the third most common disease influencing the quality of life of
many patients. Here, a programmed cell death‐ligand 1+(PD‐L1) mesenchymal stem cell …
many patients. Here, a programmed cell death‐ligand 1+(PD‐L1) mesenchymal stem cell …
Treatment after progression in the era of immunotherapy
Immunotherapy represents a paradigm shift in oncology treatment. The goal of
immunotherapy is to overcome immunosuppression induced by a tumour and its …
immunotherapy is to overcome immunosuppression induced by a tumour and its …
[HTML][HTML] Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
DS Mandlik, SK Mandlik… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the world's deadliest and fastest-growing tumors,
with a poor prognosis. HCC develops in the context of chronic liver disease. Curative …
with a poor prognosis. HCC develops in the context of chronic liver disease. Curative …
[PDF][PDF] Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint
molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies …
molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies …
Immune checkpoint inhibitor-associated colitis: from mechanism to management
L Tang, J Wang, N Lin, Y Zhou, W He, J Liu… - Frontiers in …, 2021 - frontiersin.org
Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies,
including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and …
including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and …